Metraipolis › archive › dc_bed041e834c8
Thromboembolic adverse events associated with TPO-RA in ITP treatment: a pharmacovigilance analysis of the FDA Adverse Event Reporting System — Europe PMC PMID:41766870
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41766870
- DOI
- 10.3389/fimmu.2026.1669486
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T20:43:34.174Z
- SHA-256 of the archived text
ab4f24083459ddbac0cabd167b27d96d8cce1aa3c17cb42408611a85c2d60485- Stable URL of this page
https://metraipolis.com/documento/dc_bed041e834c8
How to cite
Thromboembolic adverse events associated with TPO-RA in ITP treatment: a pharmacovigilance analysis of the FDA Adverse Event Reporting System — Europe PMC PMID:41766870 — Europe PMC (en), https://europepmc.org/article/MED/41766870 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bed041e834c8 (Metraipolis archive dc_bed041e834c8, sha256 ab4f24083459ddbac0cabd167b27d96d8cce1aa3c17cb42408611a85c2d60485)
BibTeX
@misc{dcbed041e834c8,
title = {Thromboembolic adverse events associated with TPO-RA in ITP treatment: a pharmacovigilance analysis of the FDA Adverse Event Reporting System — Europe PMC PMID:41766870},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41766870},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bed041e834c8; sha256 ab4f24083459ddbac0cabd167b27d96d8cce1aa3c17cb42408611a85c2d60485},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41766870. Agents can read the archived copy with the MCP tool read_document.